Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
Robert Hans Ingemar Andtbacka(University of Utah), Kenneth F. Grossmann(University of Utah), Adil Daud(University of California, San Francisco), Matthew H. Taylor(Providence Portland Medical Center), Rogerio I. Neves(Saint John's Health Center), John T. Vetto(Oregon Health & Science University), Richard S. Ungerleider(Unknown), Merrick I. Ross(Johns Hopkins University), Sanjiv S. Agarwala(Goethe University Frankfurt), Maki Tanaka(Takara (Japan)), Hung T. Khong(University of Utah)
Cited by 55
Related Papers
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
|Immunity|2018|937
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914